TERLIPRESSINA FA REGREDIRE LA SINDROME EPATORENALE DI TIPO 1 NEL 40% DEI CASI

CIRROSI EPATICA, EPATOLOGIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA

Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome Florence Wong, et al. Abstract BACKGROUND The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe. METHODS We conducted a phase 3 trial to confirm the efficacy…

UNO SCORE DI FACILE USO PER IDENTIFICARE IL PAZIENTE CON CIRROSI NEL TUO STUDIO

EPATOLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, SCORE & EQUATIONS

Can routine blood tests be modelled to detect advanced liver disease in the community: model derivation and validation using UK primary and secondary care data  Theresa Hydes et al. Abstract Objectives Most patients are unaware they have liver cirrhosis until they present with a decompensating event. We therefore aimed to develop and validate an algorithm to…

UN CALCOLATORE MOLTO ACCURATO PER LA PROGNOSI DEL PAZIENTE CON COVID-19

COVID19 - EVIDENCE, MEDICI DI FAMIGLIA, MEDICINA INTERNA, SCORE & EQUATIONS

Development of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19 FREE Shannon Wongvibulsin et al. Abstract Background: Predicting the clinical trajectory of individual patients hospitalized with coronavirus disease 2019 (COVID-19) is challenging but necessary to inform clinical care. The majority of COVID-19 prognostic tools…

Più di 140,000 differenti virus vivono nell’intestino umano.

MEDICINA DEI PROBIOTICI, NUTRIZIONE

Massive expansion of human gut bacteriophage diversity Luis F. Camarillo-Guerrer et al. Highlights • Database containing 142,809 non-redundant gut phage genomes from 28,060 metagenomes • Host assignment reveals phage diversity and host range across gut bacteria isolates • Epidemiology analysis unveils 280 viral clusters that are globally distributed • The Gubaphage is a clade that…

REPLICAZIONE DEGLI STUDI CONTROLLATI NELLA “REAL WORLD EVIDENCE”: UN OTTIMO EDITORIALE

REAL WORLD EVIDENCE

Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong? David Thompson1 Abstract With the growing interest in using real-world evidence (RWE) for regulatory purposes, researchers and policy makers are considering how best to assess the credibility of RWE. Because the randomized controlled trial (RCT) has long been regarded as the gold standard…